(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) announced, overall, the company expects to report net product sales of $104.3 million in 2023, representing 36% growth over 2022. For the fourth quarter, ...
Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 ...
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) and The University of Texas MD Anderson Cancer Center announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA in ...
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts. The company ...
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive trend vote on the Marketing ...
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company Rigel Pharmaceuticals has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback